Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Otsuka Licenses US Rights for PDE4 Inhibitor to Medimetriks
February 10, 2016
- Ethical Drug Sales Up 5.7% in December: Crecon Report
February 10, 2016
- Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
February 10, 2016
- Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
February 10, 2016
- Mundipharma Gearing Up for Full-Blown Oncology Business in Japan
February 9, 2016
- AZ Posts Japan Sales of US$2 Billion in 2015, Down 9% in Actual Terms
February 9, 2016
- Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
February 9, 2016
- PeptiDream Joins Hands with Shionogi, 5th Japanese Partner
February 8, 2016
- Takeda Expands ADC Collaboration with US Startup Mersana
February 5, 2016
- FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction
February 5, 2016
- Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary
February 5, 2016
- BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
February 5, 2016
- Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
February 5, 2016
- Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
February 4, 2016
- Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ
February 4, 2016
- Mitsubishi Tanabe to Shed 10-Plus % of Japan Workforce
February 4, 2016
- Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE
February 4, 2016
- Sovaldi, Harvoni Haul in Nearly US$1.9 Billion in Japan: Gilead
February 4, 2016
- Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
- Belsomra Most Promoted Drug for GPs for 6 Straight Month: Anterio
February 3, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…